tert-Butyl 5-aminoindoline-1-carboxylate

Catalog No. :
ACJXWC389
CAS No. :
129487-92-9
Molecular Formula :
C13H18N2O2
Molecular Weight :
234.30

IUPAC Name:tert-butyl 5-aminoindoline-1-carboxylate

tert-Butyl 5-aminoindoline-1-carboxylate structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
5g95%$173.00Login to see priceIn stockIn stock
25g95%$689.00Login to see priceIn stockIn stock
100g95%$2203.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Nametert-Butyl 5-aminoindoline-1-carboxylate
IUPAC Nametert-butyl 5-aminoindoline-1-carboxylate
MDL No.MFCD08059270
Molecular FormulaC13H18N2O2
Molecular Weight234.30
SMILESCC(C)(C)OC(=O)N1CCC2=CC(N)=CC=C12
InChI KeyJSNLQWAGJJGYOB-UHFFFAOYSA-N
SynonymA888849 | tert-Butyl5-aminoindoline-1-carboxylate | F12047 | SB32668 | Z332725462 | BB 0256528 | AKOS000302353 | tert-butyl-5-amino-1-indolinecarboxylate | 1-Boc-5-aminoindoline | 5-amino-2,3-dihydro-indol-1-carboxylic acid tert-butyl ester | Glibenclamid
CAS No.129487-92-9
PubChem CID22240520

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P305+P351+P338

Synthetic Route by SureRoute

1. ACJXWC389 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACJXWC389 route product structure diagram
    ACJXWC389129487-92-9 In Stock
Inquiry

2. ACJXWC389 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACBTZV437 route compound structure diagram
    ACBTZV437166104-19-4 In Stock
  2. Plus
  3. ACQVKH312 route compound structure diagram
    ACQVKH3121184-54-9 In Stock
  4. Plus
  5. reactant_3 route compound structure diagram
    --
  6. Then
  7. ACJXWC389 route product structure diagram
    ACJXWC389129487-92-9 In Stock
Inquiry

Comments (0)